{"id":"W3172838457","doi":"10.1200/jco.2021.39.15_suppl.tps2670","title":"A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Tolerability; Pembrolizumab; Stimulator of interferon genes; Oncology; Agonist; Internal medicine; Immunotherapy; Sting; Immune system; Pharmacology; Cancer; Immunology; Innate immune system; Adverse effect; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001168466,0.001750398,0.002156568,0.0005557991,0.0004393325,0.001128275,0.0007882821,0.001298552,0.003392929],"category_scores_gemma":[0.0009183392,0.0007309818,0.001278379,0.0004256759,0.001052625,0.001272132,0.0003848934,0.004440586,0.0009532506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001009588,"about_ca_system_score_gemma":0.001312631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005507859,"about_ca_topic_score_gemma":0.001219291,"domain_scores_codex":[0.9995548,0.0001635643,0.00002055769,0.0001171704,0.0000451146,0.00009866496],"domain_scores_gemma":[0.9993322,0.00008640897,0.000151514,0.0000715487,0.00004221841,0.0003161046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6714022,0.1690772,0.004570389,0.0006327026,0.001093971,0.0002534682,0.000410937,0.003003767,0.07448633,0.0002792056,0.002227338,0.07256256],"study_design_scores_gemma":[0.2401176,0.7433574,0.00741794,0.00001746183,0.0003843957,0.0002074335,0.00006096186,0.001028365,0.005500469,0.0001817917,0.001698059,0.00002820347],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944008,0.0008814364,0.0006527185,0.0002351369,0.0001093952,0.001999987,0.0006143201,0.00007980447,0.001026312],"genre_scores_gemma":[0.9914644,0.0008078667,0.001741897,0.0004808445,0.0001254459,0.002246246,0.0009512594,0.00002786235,0.002154264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003392929,"threshold_uncertainty_score":0.01135051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07458423942254296,"score_gpt":0.4116550165163493,"score_spread":0.3370707770938064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}